Physician profile
Stephan A Ames
NPI 1437109154
$5,617.37
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $1,603 · 2021: $2,254 · 2022: $164.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,201.80 | 2019-2021 | |
| Amgen INC. | $672.34 | 2019-2021 | |
| Pfizer INC. | $536.57 | 2019-2021 | |
| Abbvie INC. | $524.78 | 2019-2022 | |
| Novo Nordisk INC | $251.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $237.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.81 | 2019-2022 | |
| Amarin Pharma, INC. | $199.65 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $169.32 | 2020-2022 | |
| Daiichi Sankyo INC. | $160.17 | 2020-2022 | |
| Lilly USA, LLC | $133.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.69 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $122.98 | 2019-2022 | |
| Therapeuticsmd, INC. | $94.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $82.78 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $82.18 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $77.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $76.94 | 2019-2021 | |
| Astellas Pharma US INC | $75.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $69.05 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $67.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.18 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $52.48 | 2021 | |
| Boston Scientific Corporation | $43.13 | 2021 | |
| Horizon Therapeutics Plc | $30.54 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.96 | 2021 | |
| Lundbeck LLC | $24.10 | 2021 | |
| Mannkind Corporation | $22.95 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.17 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.45 | 2021 | |
| Genentech USA, INC. | $16.33 | 2019 | |
| Philips North America LLC | $12.00 | 2020 | |
| Allergan, INC. | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.